The US Food and Drug Administration (FDA) has accepted Alpha Cognition’s new drug application (NDA) for ALPHA-1062 to treat mild-to-moderate Alzheimer’s disease.
The regulatory agency will provide a decision on the approval of the treatment on 27 July 2024 under the Prescription Drug User Fee Act.
Go deeper with GlobalData
Alpha Cognition filed the NDA for ALPHA-1062 with the FDA in September 2023.
The filing is based on findings from four clinical trials that showed ALPHA-1062 to be bioequivalent to galantamine and galantamine ER.
Adverse events associated with ALPHA-1062 in these studies were reported to be under 2%. Insomnia was not noted among them.
See Also:
Alpha Cognition CEO Michael McFadden stated: “The FDA’s acceptance of our NDA for ALPHA-1062 brings us another significant step closer to delivering a much-needed treatment to patients suffering from Alzheimer’s disease.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“We look forward to continuing our collaboration with the FDA throughout the review process.”
The clinical-stage biopharmaceutical company focuses on the development of therapies for treating neurodegenerative diseases such as Alzheimer’s and cognitive impairment with mild traumatic brain injury (mTBI).
A delayed-release oral tablet formulation, ALPHA-1062 is in development as a new-generation inhibitor of acetylcholinesterase.
The active metabolite of this new entity is differentiated from donepezil and rivastigmine as it attaches to the neuronal nicotinic receptors, especially to the alpha-7 subtype, which has a positive impact on cognition.
ALPHA-1062 is a pro-drug of galantamine and cuts down gastrointestinal-based adverse effects by remaining inert while passing through the stomach.
Therapies currently approved for Alzheimer’s have substantial adverse events including nausea, diarrhoea and insomnia.
Some patients therefore find them unpleasant and impractical to use over longer periods. This has led to an unmet need for effective and tolerable treatments for Alzheimer’s disease.
ALPHA-1062 is also being developed for use along with memantine for moderate to severe Alzheimer’s dementia and as an intranasal dose to treat cognitive impairment linked to mTBI.
